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Abstract
Background:  Epstein-Barr virus (EBV) infection immortalizes primary B cells in vitro and
generates lymphoblastoid cell lines (LCLs), which are used for several purposes in immunological
and genetic studies. Purinergic receptors, consisting of P2X and P2Y, are activated by extracellular
nucleotides in most tissues and exert various physiological effects. In B cells, especially EBV-induced
LCLs, their expression and function have not been well studied. We investigated the expression of
P2 receptors on primary human B cells and LCLs using the quantitative reverse transcriptase-
polymerase chain reaction (RT-PCR) method for revealing the gene expression profile of the P2
receptor subtypes and their changes during transformation.
Results: The mRNA transcripts of most P2 receptors were detected in primary B cells; the
expression of P2X3 and P2X7 receptors was the lowest of all the P2 receptors. By contrast, LCLs
expressed several dominant P2 receptors – P2X4, P2X5, and P2Y11 – in amounts similar to those
seen in B cells infected with EBV for 2 weeks. The amount of most P2 subtypes in LCLs or EBV-
infected B cells was lower than in normal B cells. However, the amount of P2X7 receptor expressed
in LCLs was higher. Protein expression was studied using Western blotting to confirm the mRNA
findings for P2X1, P2X4, P2X7, P2Y1, and P2Y11 receptors. ATP increased the intracellular free Ca2+
concentration ([Ca2+]i) by enhancing the Ca2+ influx in both B cells and LCLs in a dose-dependent
manner.
Conclusion: These findings describe P2 receptor expression profiles and the effects of purinergic
stimuli on B cells and suggest some plasticity in the expression of the P2 receptor phenotype. This
may help explain the nature and effect of P2 receptors on B cells and their role in altering the
characteristics of LCLs.
Background
B cells synthesize and secrete large quantities of soluble
immunoglobulin antibodies and thus, play a key role in
humoral immunity. An infection with the Epstein-Barr
virus (EBV) easily transforms resting primary B cells in
vitro from human peripheral blood cells into B-blast-like
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proliferating lymphoblastoid cell lines (LCLs) [1]. This
infection is used routinely in the laboratory to generate
LCLs from B cells [2]. LCLs are widely used in various
types of studies, including those involving the disciplines
of immunology, cellular biology, and genetics. This trans-
formation results in changes in certain cellular properties,
including gene expression [3], cell surface phenotyping,
and cytokine production [4].
Extracellular nucleotides – e.g., adenosine 5'-triphosphate
(ATP), adenosine 5'-diphosphate, uracil 5'-triphosphate,
and uracil 5'-diphosphate – have various physiological
effects in many cells, such as exocrine and endocrine
secretion, neurotransmission, cell proliferation, cell dif-
ferentiation, and programmed cell death that are medi-
ated by P2 receptors, consisting of P2X and P2Y receptors
[5]. P2X receptors are ligand-gated cation channels, of
which seven receptor subtypes (P2X1 to P2X7) have been
identified and cloned [6]. P2Y receptors, which are G-pro-
tein-coupled metabotropic structures, consist of eight
cloned and functionally distinct subtypes: P2Y1, P2Y2,
P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14 [5,7].
Blood cells express P2 receptors which regulate such
responses as cell proliferation, differentiation, chemo-
taxis, cytokine release, immune and inflammatory
responses [5,8]. In lymphocytes, ATP induces an increase
in membrane permeability for cations and larger mole-
cules [9,10], as well as cellular proliferation [11] and cell
death through P2 receptors [12,13]. The precise nature of
the expression and function of the P2 receptor subtypes
have been investigated [14-16].
P2 receptors expressed in B cells have been investigated
using electrophysiological, pharmacological, and immu-
nocytochemical techniques, which have revealed the
existence of P2 receptors [17], especially P2X [14,18].
However, the researchers in these studies failed to perform
a quantitative analysis of P2 mRNA and used B cells from
chronic lymphocytic leukemia (CLL) or LCLs, rather than
pure B cells. Recently, the mRNA profile of the lym-
phocyte P2 receptor was subjected to quantitative analy-
sis, but the B cells were not separated and not all subtypes
were targeted [15,16].
In this study, we investigated the expression of P2 recep-
tors in human B cells and in LCLs using quantitative
reverse transcriptase-polymerase chain reaction (RT-PCR),
Western blotting, and fluorimetric techniques to measure
intracellular free Ca2+ concentration ([Ca2+]i). We were
able to determine the profile of the P2 receptor mRNA in
these cells and monitor changes in [Ca2+]i in response to
P2 receptor activation. Our findings indicate the plasticity
of P2 receptors in B cells during their transformation into
LCLs.
Results
IgD and CD38 are cell-surface molecules that have been
used widely to identify the B-cell phenotype during B-cell
development. Like germinal center B cells, most EBV-
transformed B cells were positive for CD38 but not for IgD
[19,20]. The expression of IgD and CD38 molecules on
primary B cells and EBV-transformed LCLs was evaluated
by fluorescence-activated cell sorter (FACS) analysis. To
generate LCLs, we cultured isolated B cells with the active
EBV supernatant for 4 to 6 weeks, as described in Methods
section. The primary B cells expressed IgD, but not CD38,
and the LCLs expressed CD38, but not IgD (data not
shown). This result is consistent with our previous find-
ings [20].
P2 receptor mRNA quantification
The expression of P2 receptors in B cells and LCLs was
determined using quantitative RT-PCR. The expression of
the P2 receptor subtypes was compared among B cells,
LCLs, and peripheral blood mononuclear cells (PBMCs).
P2X1 or P2Y1 were used as a calibrator (i.e. the P2X recep-
tor was expressed as a ratio of P2X1 and the P2Y receptor
as P2Y1) in order to illustrate the expression of P2 recep-
tors relative to each other. All P2X and P2Y receptor sub-
types were detected in the B cells. Most of the P2 receptor
subtypes had similar rates of expression within 1- or 2-
fold of each other with the exception of the P2X3 and P2X7
receptors, which were expressed in lower quantities (Fig-
ure 1, n = 4). P2X7 receptor expression was significantly
low compared to other P2X receptors (p < 0.05), with the
exception of P2X3. The presence of P2X- and P2Y-receptor
mRNA in the B cells is in agreement with the findings of
previous lymphocyte studies using RT-PCR [15,16]. EBV-
infected B cells were also examined because an in vitro
transformation might alter the expression of receptors.
The most abundant P2 receptor subtypes were P2X4, P2X5,
and P2Y11 (Figure 2; n = 4). The expression of P2X5 recep-
tors in LCLs was significantly higher than other P2X recep-
tors (p < 0.05; Figure 2). The P2 receptors in B cells were
compared with those expressed in LCLs (Figure 3, P2X1 of
B cells used as a P2X calibrator and P2Y1 as a P2Y calibra-
tor). The expression of the P2X1 through to P2X6 receptors
and P2Y receptors in LCLs and B cells that had been
infected with EBV for 2 weeks was significantly lower than
in noninfected B cells (p < 0.01; Figure 3). However, the
LCLs expressed a significantly larger number of P2X7
receptors than B cells (p < 0.01; Figure 3). The expression
of EBV-infected LCLs, which had been infected for more
than 4 weeks and EBV-infected B cells, which had been
infected for 2 weeks, yielded similar profiles and quanti-
ties. As a control, P2 receptors in PBMCs were quantified
and these showed a different expression profile. In
PBMCs, which are mainly monocytes and lymphocytes,
P2X4, P2Y6, P2Y11, and P2Y13 were the predominant P2
receptor subtypes (Figure 4, n = 4), and the expressionBMC Immunology 2006, 7:22 http://www.biomedcentral.com/1471-2172/7/22
Page 3 of 11
(page number not for citation purposes)
rates for P2X4 and P2Y6 were significantly higher than
other P2X or P2Y subtypes (p < 0.001). In addition, P2X4,
P2X7, P2Y6, P2Y11, and P2Y13 expression was significantly
higher in PBMCs compared with B cells (p < 0.05), which
may be the result of T cell/monocyte contamination in the
PBMC preparation [15,16]. Therefore, the up-regulated
P2X7 receptor can be expected to have a physiological role
during the transformation of B cells into LCLs.
Western blotting for P2 receptors
To investigate the correlation of mRNA with protein, we
carried out Western blot analysis for P2X1, P2X4, P2X7,
P2Y1, and P2Y11  receptors, all of which had varying
amounts of mRNA during EBV transformation (n = 4).
The distribution of P2 receptors in B cells and LCLs is
shown on the left panel (Figure 5). The bands represent-
ing P2X1 (60-kDa), P2X4 (65-kDa), P2Y1 (66-kDa), and
P2Y11 (50-kDa) receptors were more prominent in B cells
than in LCLs, which correlates with the results of the
mRNA quantitative analysis. As for the P2X7 receptor, it
was represented by a prominent 68-kDa band in LCLs and
a faint band in B cells. This is consistent with the results of
RT-PCR, which indicated that the expression of P2X7 is
higher in LCLs than in B cells. To compare protein load-
ing, the blot was re-probed with anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibody (40-kDa)
(Figure 5, right).
Effect of ATP on intracellular free Ca2+ concentration
Extracellular ATP is an effective modulator of [Ca2+]i, and
its activities are mediated through P2 receptors [17]. To
determine whether the P2 receptors examined by RT-PCR
Relative expression of P2 receptors in LCLs Figure 2
Relative expression of P2 receptors in LCLs. The rela-
tive expression of the P2X receptor gene (upper) and P2Y 
receptor gene (lower) in EBV-infected B cells (2 wks), LCLs, 
are presented (n = 4). The expression was normalized to 
GAPDH. P2X receptors were calibrated by P2X1 and P2Y 
receptors were calibrated by P2Y1. Data are the mean ± 
SEM.
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Relative expression of P2 receptors in B cells Figure 1
Relative expression of P2 receptors in B cells. The rel-
ative expression of the P2X receptor gene (upper; P2X1, 
P2X2, P2X3, P2X4, P2X5, P2X6, and P2X7) and P2Y receptor 
gene (lower; P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, 
and P2Y14) in B cells are presented (n = 4). The expression 
was normalized to GAPDH. P2X receptors were calibrated 
by P2X1 and P2Y receptors were calibrated by P2Y1. Data 
are the mean ± SEM.
P2X1 P2X2 P2X3 P2X4 P2X5 P2X6 P2X7
0.0
0.5
1.0
1.5
2.0
2.5
R
a
t
i
o
 
o
f
 
T
a
r
g
e
t
/
P
2
X
1
P2Y1 P2Y2 P2Y4 P2Y6 P2Y11 P2Y12 P2Y13 P2Y14
0.0
0.5
1.0
1.5
2.0
2.5
R
a
t
i
o
 
o
f
 
T
a
r
g
e
t
/
P
2
Y
1BMC Immunology 2006, 7:22 http://www.biomedcentral.com/1471-2172/7/22
Page 4 of 11
(page number not for citation purposes)
and Western blotting were functional, we carried out dig-
ital fluorescence imaging of the Ca2+-sensitive dye Fura 2-
AM and compared the images seen following ATP-
induced changes in [Ca2+]i in B cells and LCLs. In the pres-
ence of 2 mM Ca2+ and 1 mM ATP, we observed an average
increase in [Ca2+]i  from 0.1 to 0.5 (representing the
F340:F380 ratio) in B cells and LCLs (Δratio of B cells:
0.32 ± 0.04, n = 6; Δratio of LCLs: 0.39 ± 0.04, n = 6) (Fig-
ures 6A and 6B). The [Ca2+]i increased with ATP in a dose-
dependent manner (100–1000 μM; n = 25) (Figure 6C),
indicating that the potency of ATP was similar in both
cells. The mechanism leading to the intracellular Ca2+
response was examined further by repeating these experi-
ments under Ca2+-free conditions. The B cells were treated
with 1 mM ATP under Ca2+-free conditions, and the
[Ca2+]i remained at or near the pre-agonist levels (Figure
7A). The peak [Ca2+]i was mostly abolished in B cells (n =
14, p < 0.0001) and in LCLs (n = 12, p < 0.0001) in the
absence of Ca2+ (Figure 7B). These data suggest that an
influx of Ca2+ is the major route by which B cells and LCLs
respond to ATP stimulation.
Discussion
In this study, we determined and compared mRNA
expression levels for all known P2X and P2Y receptor sub-
types on human B cells and LCLs. Quantitative RT-PCR
was used to determine the gene expression profile for P2
receptors. This method was selected because selective ago-
nists and antagonists for most of the P2 receptor subtypes
are absent and real-time PCR has advantages over other
methods, such as requiring only a small number of cells
and being one of the most reliable methods of determin-
ing the amount of RNA.
This is the first study to show the expression of P2 recep-
tors using mRNA from healthy human B cells. In these
cells, most of the P2X and P2Y receptor subtypes had 2-
Relative expression of P2 receptors in PBMCs Figure 4
Relative expression of P2 receptors in PBMCs. The 
relative expression of the P2X receptor gene (upper) and 
P2Y receptor gene (lower) in PBMCs are presented (n = 4). 
The expression was normalized to GAPDH. P2X receptors 
were calibrated by P2X1 and P2Y receptors were calibrated 
by P2Y1. Data are the mean ± SEM.
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Comparison of relative P2 receptor expression in B cells and  LCLs Figure 3
Comparison of relative P2 receptor expression in B 
cells and LCLs. The relative expression of the P2X recep-
tor gene (upper) and P2Y receptor gene (lower) in B cells, 
EBV-infected B cells for 2 weeks, and LCLs are presented (n 
= 4). The expression was normalized to GAPDH. P2X recep-
tors were calibrated by P2X1 of B cells and P2Y receptors 
were calibrated by P2Y1 of B cells. Data are the mean ± SEM.
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fold expression with the exception of P2X3  and P2X7
receptors. In the studies of the P2X receptor, the P2X1,
P2X2, P2X4, and P2X7 receptors were found in human B
cells by an immunocytochemical assay [14] and the non-
desensitizing cation channels activated by ATP, which is a
feature of P2X7 receptor, were measured using electro-
physiological methods [18]. The different results of P2X
subtype expression might be due to the different B cells, or
variations in P2X receptor expression [21]. B cells trans-
formed by EBV [18] or malignant B cells [14] were used in
previous studies, while normal B cells were used in the
present study. In addition, it is possible that there might
be differences in the transcription, translation, and func-
tion of P2X receptors. The different P2X7 expression levels
may be because P2X7 receptor might be up-regulated in
CLLs [10] and that some lymphoid cells do not express
P2 receptors (P2X1, P2X4, P2X7, P2Y1, and P2Y11) compared by Western blotting in B cells and LCLs Figure 5
P2 receptors (P2X1, P2X4, P2X7, P2Y1, and P2Y11) compared by Western blotting in B cells and LCLs. Proteins 
extracted from B cells and LCLs were probed with rabbit polyclonal antibodies directed against P2X1 (60-kDa), P2X4 (65-kDa), 
P2X7 (68-kDa), P2Y1 (66-kDa), and P2Y11 (50-kDa) (left). Membranes were re-probed by GAPDH (40-kDa) (right). Data are 
representatives of 4 independent experiments.
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GAPDH
B cells LCLs
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P2X7 receptor [11]. In addition, B cells did not undergo
the typical increase in membrane permeability to ATP and
were not susceptible to ATP-mediated cytotoxicity [8,22].
Although the P2Y receptors in B cells were investigated, it
was not enough to compare the expression of subtypes.
P2Y subtypes were detected by RT-PCR in previous stud-
ies, albeit only in lymphocytes [15,16].
In LCLs and B cells infected by EBV for 2 weeks, the pre-
dominant P2 receptor subtypes were P2X1, P2X4, P2X5,
P2X7, and P2Y11. The expression of most P2 receptors was
suppressed during the EBV-induced B-cell transformation
into LCLs, however, the suppression of P2X1, P2X4, P2X5
and P2Y11 receptors was not as great as for other subtypes.
Effect of extracellular Ca2+-free conditions on [Ca2+]i induced  by ATP Figure 7
Effect of extracellular Ca2+-free conditions on [Ca2+]i 
induced by ATP. (A) Average time courses for Ca2+ 
responses induced by external perfusion of ATP (1 mM) in 
normal solution and the Ca2+-free solution in B cells (n = 4). 
Agent was applied as indicated by the horizontal bars above 
the traces. (B) Peak of ATP-induced [Ca2+]i rises during pre-
treatment with the Ca2+-free solution (n = 14 for B cells; n = 
12 for LCLs). Data are the mean ± SEM; *p < 0.0001 com-
pared to Ca2+ treated samples.
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Comparison of ATP-induced increases in [Ca2+]i in B cells  and LCLs Figure 6
Comparison of ATP-induced increases in [Ca2+]i in B 
cells and LCLs. (A, B) Average time courses for Ca2+ 
responses to P2 receptor stimulation with ATP (1 mM) in B 
cells (A, n = 6) and in LCLs (B, n = 6). ATP was applied as 
indicated by the horizontal bars above the traces. (C) Con-
centration-response curve for the increase in [Ca2+]i in 
response to ATP in B cells and in LCLs (Δratio F340/F380). 
ATP increased [Ca2+]i in a dose-dependent manner. The 
maximum increase in the [Ca2+]i over basal is plotted against 
the concentration of ATP. The measurement of [Ca2+]i was 
carried out in single cells attached to a coverslip, as 
described in the Methods section. Data are the mean ± SEM 
for at least 25 cells on 4 to 5 coverslips.
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Only P2X7 receptor was significantly up-regulated. West-
ern blotting showed similar patterns for P2X1, P2X4, P2X7,
P2Y1, and P2Y11, as well as for P2X2, P2X5, P2Y2, and P2Y6
(data not shown). Our results suggest that there is some
plasticity in P2-receptor expression in B cells. This possi-
bility has been investigated in many tissues and cells,
including the urinary bladder, heart, vessels, gut, neurons,
and cancer cells [5]. In immune cells, plasticity in P2Y2-
receptor expression was studied during myeloid leukocyte
differentiation [23]. Sensitivity to ATP in thymocytes
changes with the stage of maturation [24,25], and P2X7-
receptor expression can be modulated by diverse stimuli
[26]. The plasticity of P2 receptors may be due to changes
in their exposure to ATP or EBV-induced changes in gene
expression. In vivo, ATP is often released by blood cells
into the extracellular environment through nonlytic
mechanisms. Some leakage of cytoplasmic ATP may also
occur as a consequence of damage to the cell or acute cell
death. Platelet-dense granules comprise another relevant
source of ATP [8]. In vitro, however, the sources of ATP for
B cells are limited to nonlytic mechanisms or leakage of
cytoplasmic ATP. The EBV-induced transformation of B
cells into LCLs results in some B cells dying, which results
in ATP being released into the extracellular compartment,
where it continually degrades. Thus, the concentration of
ATP may be high in the early stages of in vitro transforma-
tion and lower in later stages. The expression of P2 recep-
tors may be affected by this fluctuation in environmental
ATP.
In PBMC populations that include lymphocytes and
monocytes, the dominant P2 receptor subtypes were
P2X4, P2Y6, P2Y11, and P2Y13. An mRNA expression assay
revealed that the P2Y1, P2Y2, P2Y4, and P2Y6 receptors
were expressed in lymphocytes and monocytes and that
the P2Y6  receptor was expressed in relatively higher
amounts than the other P2Y receptor subtypes [16]. P2X4
and P2Y12 receptors were expressed in relatively large
amounts in lymphocytes and P2X4, P2Y2, and P2Y13
receptors in monocytes [15]. The expression of P2X4,
P2Y6, and P2Y13 receptors correlated with the findings of
previous studies; however, the expression of the P2Y11
receptor was somewhat different. It is possible that other
lymphocytes or monocytes expressed these subtypes pre-
dominantly. Alternatively this may reflect a variation in
cohorts or contamination with other types of blood cells.
To date, these blood cells have not been investigated well
enough to compare P2 receptor subtypes, although some
of them have been surveyed [5,8,16,27,28]. Because the
P2 receptor profiles of blood cells are not completely
known, it is difficult to determine which P2 receptor sub-
types have been expressed dominantly in PBMCs until
now.
Although the P2Y8 and P2Y10 receptors were examined
with other subtypes, the findings for these subtypes were
omitted because they are not included among the classical
P2Y receptor subtypes in humans. We found the mRNA
for these subtypes in B cells, LCLs, and PBMCs, indicating
that they are prominent in these cells. In previous studies
of human P2 receptors, the P2Y8 and P2Y10 receptors were
expressed in HL60 [29] and included in the human
genome [30]. The National Center for Biotechnology
Information (NCBI) confirmed the gene sequence for
each of these receptors (P2Y8; NM_178129, P2Y10;
NM_014499). A physiological role for the P2Y8 and P2Y10
receptors in B cells and in human blood cells can therefore
be expected.
ATP-stimulated P2 receptors increased the [Ca2+]i in B
cells and LCLs, albeit rather slowly. This was quite a differ-
ent effect from that of other stimuli, such as the anti-IgM
antibody, which caused [Ca2+]i levels to change rapidly
[31]. This might be due to differences in Ca2+ signaling or
the temperature at which the experiments were con-
ducted, which might influence the kinetics involved when
the [Ca2+]i changes. Extracellular Ca2+-free conditions pre-
vented the [Ca2+]i from increasing, thereby indicating that
the main cause of the increase in [Ca2+]i might be an ATP-
induced influx of Ca2+, although the possibility that
mobilization of stored Ca2+ may be involved should prob-
ably also be considered. The increased [Ca2+]i might be
largely due to P2X receptor activity, because it was medi-
ated by an influx of Ca2+, which is the major effect of acti-
vating P2X receptors. The results of real-time PCR
indicated a decrease in P2 receptors and those of Western
blotting demonstrated a similar pattern for several P2
receptors, even when the up-regulation of P2X7 receptor
was considered. However, the increase in [Ca2+]i by ATP
was a little higher in LCLs than in B cells, which was not
statistically significant. EBV-transformed B cells might
enhance the availability of Ca2+, thereby causing [Ca2+]i to
rise, even when P2 receptors are down-regulated. The
response to extracellular ATP is an increase in [Ca2+]i in B
cells as well as in LCLs, which are probably derived from
EBV-infected B cell lymphoma in vivo. This may cause a
variety of cellular events, ranging from transcriptional reg-
ulation to cell migration and proliferation.
Conclusion
In this study, the expression of P2X and P2Y receptors in
human B cells and LCLs was investigated. P2-receptor
expression was suppressed during the EBV-induced trans-
formation of B cells, except for the P2X7 subtype, which
was up-regulated. Extracellular ATP induced an increase in
[Ca2+]i in B cells and LCLs via P2 receptors. Therefore,
these findings reveal the exact P2 receptor profiles and the
effects of purinergic stimuli on B cells and suggest some
plasticity in the expression of the P2 receptor phenotype.BMC Immunology 2006, 7:22 http://www.biomedcentral.com/1471-2172/7/22
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This will help us explain the nature and effect of P2 recep-
tors on B cells and their role in altering the characteristics
of LCLs.
Methods
B-cell purification and generation of EBV-transformed 
LCLs
Ten 240-mL packs of blood were obtained from the Cen-
tral Red Cross Blood Center (Seoul, Korea). This blood
was not appropriate for transfusion because of slightly ele-
vated alanine aminotransferase levels. We used it to iso-
late PBMCs, using Ficoll-Hypaque gradient centrifugation
(Amersham Biosciences, Uppsala, Sweden) and B cells,
which were purified (>95% CD20+) using a B-cell isola-
tion kit and a MACS separator (Miltenyi Biotec, Bergisch
Gladbach, Germany). The immortalization of B cells was
achieved by EBV infection [2,32-34]. The B95-8 superna-
tant was added to the purified B cells in a culture flask (1
× 106 cells/mL). Following a 2-hour incubation period at
37°C, the same volume of medium and 0.5 μg/mL
cyclosporine A [35] were added. The cultures were incu-
bated for 4 to 6 weeks until clumps of EBV-infected B cells
were visible. EBV-transformed LCLs were cultured in
RPMI-1640 medium (GIBCO/BRL, Grand Island, NY,
USA) supplemented with 10% heat-inactivated fetal
bovine serum (FBS) (BioWhittaker, Walkerville, MD,
USA) and 1% (v/v) antibiotics/antimycotics that included
penicillin G (100 IU/mL), streptomycin (100 μg/mL), and
amphotericin B (0.25 μg/mL). The cells were cultured in a
humidified atmosphere of 5% CO2 and 95% air at 37°C.
The EBV stock was prepared from an EBV-transformed
B95-8 marmoset cell line. These cells were grown in an
RPMI-1640 medium supplemented with 10% FBS, and
infectious culture supernatants were harvested and stored
at -80°C until needed. Thus, each pack of blood was used
to produce B cells, EBV-infected B cells, LCLs, and PBMCs
for use in this experiment. The study was approved by the
Institutional Review Board at the National Institute of
Health, Korea Center for Disease Control and Prevention.
Quantitative real-time RT-PCR
The total cellular RNA was collected from human B cells,
LCLs, and PBMCs. RNA was extracted using the RNeasy
mini kit (Qiagen, Valencia, CA, USA) according to the
manufacturer's instructions and stored at -80°C until
used. Quantitative RT-PCR was performed to determine
the expression of the P2 receptor genes (Table 1). To gen-
erate cDNA, we induced reverse transcription of the total
RNA using oligodT15 (Roche Diagnostics GmbH, Man-
nheim, Germany) and reverse transcription polymerase
(Promega, Madison, WI, USA). Oligonucleotide primers
(Bioneer, Daejeon, Korea) were designed using Primer
Express software (Applied Biosystems, Foster City, CA,
USA), based on sequences obtained from the GenBank
database, and tested for quality and efficiency. Primer effi-
ciency was established to ensure optimal amplification of
our samples. Serial dilutions of synthetic cDNAs were car-
ried out according to the supplier's instructions to define
relative changes in quantity. Real-time PCR was per-
formed using SYBR Green PCR Master mix (Applied Bio-
systems) in an ABI PRISM 7900 HT Sequence Detection
System (Applied Biosystems). The amplification program
included activation of AmpliTaq Gold at 95°C for 10 min-
utes, followed by 45 cycles of 2-step PCR with denatura-
tion at 95°C for 15 seconds and annealing/extension at
60°C for 1 minute. Amplifications were followed by a
melting curve analysis. A negative control (no cDNA tem-
plate) was run simultaneously with every assay. The PCR
from each cDNA sample was run in triplicate. Constitu-
tively expressed GAPDH was selected as an endogenous
control to correct any potential variation in RNA loading
or in the efficiency of the amplification reaction. Results
are presented as relative fold changes by using GAPDH as
a reference and P2X1 or P2Y1 as a calibrator and applying
the formula 2-ΔΔCt [36].
Western blotting
Cells were lysed in RIPA buffer containing 150 mM NaCl,
50 mM Tris-Cl (pH 7.2), 1% sodium deoxycholate, 0.1%
SDS, 1 μg/mL aprotinin, 1 mM EGTA, 1 mM PMSF, and 1
mM sodium orthovanadate. After incubation in ice for 20
minutes on a shaking platform, the samples were centri-
fuged at 10,000 × g for 5 minutes at 4°C. Proteins were
mixed with the sample buffer (50 mM Tris-Cl, pH 6.8,
10% glycerol, 2% SDS, 1% mercaptoethanol, and 0.1%
bromophenol blue), heated to 95°C for 5 minutes, and
separated on a 10% SDS-PAGE gel. The gel was transferred
to polyvinylidene difluoride membranes (Amersham
Pharmacia Biotech, Buckingshire, UK) and blocked in
TBST (20 mM Tris-Cl, pH 7.6, 137 mM NaCl, 2.7 mM KCl,
and 0.1% Tween 20) containing 5% (v/v) nonfat milk
powder for 2 hours at room temperature. The membrane
was incubated with rabbit polyclonal antibodies (Alo-
mone Labs, Jerusalem, Israel) against P2X1 receptor, P2X4
receptor, P2X7 receptor, P2Y1 receptor, or P2Y11 receptor
in TBST for 2 hours at room temperature, washed with
TBST, and incubated with secondary anti-rabbit IgG
(Amersham Pharmacia Biotech) in TBST for 1 hour. After
the membrane was washed in TBST, protein bands were
visualized using Western Lightning (PerkinElmer Life Sci-
ences Inc., Gaithersburg, MD, USA). To compare protein
loading, the blot was re-probed with anti-GAPDH anti-
body (Novus Biologicals, Littleton, CO, USA).
Intracellular Ca2+ measurements
The [Ca2+]i was measured using a single-cell microscopy
technique with Fura 2 [31,37]. B cells and LCLs were sus-
pended in culture and allowed to attach to glass coverslips
coated with Poly-L-lysine (100 μg/mL; Sigma-Aldrich, St.
Louis, MO, USA) and incubated for at least 3 hours beforeBMC Immunology 2006, 7:22 http://www.biomedcentral.com/1471-2172/7/22
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use. The cells were loaded with the cell-permeable Ca2+
indicator Fura 2-AM (5.0 μM; Molecular Probes, Eugene,
OR, USA) in the culture medium for 1 hour at room tem-
perature and then washed and bathed in an external solu-
tion (135 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM
MgCl2, 10 mM glucose, and 10 mM HEPES at pH 7.4) for
at least 20 minutes before Ca2+ measurements were made.
Glass coverslips were placed into a chamber (Warner
Instrument, Hamden, CT, USA) on an inverted micro-
scope (Olympus, Tokyo, Japan), and the fluorescence
intensities of the Fura-2-loaded cells were measured using
a digital fluorescence imaging system. Discrete bandwidth
excitation light (340 nm, 380 nm) was delivered to the
epifluorescence attachment of the microscope through a
quartz fiber-optic guide. The fluorescence emitted by the
Fura-2-loaded cells was passed through a 510-nm-long
pass filter, and images were obtained using a cooled
charge-coupled device camera (Roper Scientific, Trenton,
Table 1: Sequence details for all P2X and P2Y receptor subtypes and reference (GAPDH) primers.
Receptor/Gene accession Direction Sequence Position
P2X1 Forward 5'-CGCCTTCCTCTTCGAGTATGA-3' 471 – 491
NM_002558 Reverse 5'-AGATAACGCCCACCTTCTTATTACG-3' 538 – 514
P2X2 Forward 5'-GCCTACGGGATCCGCATT-3' 958 – 975
NM_170682 Reverse 5'-TGGTGGGAATCAGGCTGAAC-3' 1024 – 1005
P2X3 Forward 5'-GCTGGACCATCGGGATCA-3' 135 – 152
NM_002559 Reverse 5'-GAAAACCCACCCTACAAAGTAGGA-3' 205 – 182
P2X4 Forward 5'-CCTCTGCTTGCCCAGGTACTC-3' 1108 – 1128
NM_002560 Reverse 5'-CCAGGAGATACGTTGTGCTCAA-3' 1176 – 1155
P2X5 Forward 5'-CTGCCTGTCGCTGTTCGA-3' 311 – 328
NM_002561 Reverse 5'-GCAGGCCCACCTTCTTGTT-3' 378 – 360
P2X6 Forward 5'-AGGCCAGTGTGTGGTGTTCA-3' 488 – 507
AF065385 Reverse 5'-TCTCCACTGGGCACCAACTC-3' 555 – 536
P2X7 Forward 5'-TCTTCGTGATGACAAACTTTCTCAA-3' 401 – 425
NM_002562 Reverse 5'-GTCCTGCGGGTGGGATACT-3' 476 – 458
P2Y1 Forward 5'-CGTGCTGGTGTGGCTCATT-3' 1352 – 1370
NM_002563 Reverse 5'-GGACCCCGGTACCTGAGTAGA-3' 1419 – 1399
P2Y2 Forward 5'-GAACTGACATGCAGAGGATAGAAGAT-3' 1495 – 1520
NM_176072 Reverse 5'-GCCGGCGTGGACTCTGT-3' 1567 – 1551
P2Y4 Forward 5'-CCGTCCTGTGCCATGACA-3' 725 – 742
NM_002565 Reverse 5'-TGACCGCCGAGCTGAAGT-3' 793 – 776
P2Y6 Forward 5'-GCCGGCGACCACATGA-3' 1171 – 1186
NM_176797 Reverse 5'-GACCCTGCCTCTGCCATTT-3' 1227 – 1209
P2Y11 Forward 5'-CTGGAGCGCTTCCTCTTCAC-3' 511 – 530
NM_002566 Reverse 5'-GGTAGCGGTTGAGGCTGATG-3' 586 – 567
P2Y12 Forward 5'-AGGTCCTCTTCCCACTGCTCTA-3' 318 – 339
NM_022788 Reverse 5'-CATCGCCAGGCCATTTGT-3' 385 – 368
P2Y13 Forward 5'-GAGACACTCGGATAGTACAGCTGGTA-3' 223 – 248
NM_023914 Reverse 5'-GCAGGATGCCGGTCAAGA-3' 291 – 274
P2Y14 Forward 5'-TTCCTTTCAAGATCCTTGGTGACT-3' 433 – 456
NM_014879 Reverse 5'-GCAGAGACCCTGCACACAAA-3' 505 – 486
GAPDH Forward 5'-CCACCCATGGCAAATTCC-3' 227 – 244
NM_002046 Reverse 5'-TGGGATTTCCATTGATGACAAG-3' 295 – 274BMC Immunology 2006, 7:22 http://www.biomedcentral.com/1471-2172/7/22
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NJ, USA). Fluorescent video images were averaged, digi-
tized (0.3–1.0 Hz), and analyzed using Metafluor acquisi-
tion and analysis software (Universal Imaging Corp, West
Chester, PA, USA). Individual cells in the field of view
were selected and paired 340/380 images were subtracted
from the background. The Fura-2 fluorescence ratios,
indicative of changes in [Ca2+]i, were calculated and their
changes were extracted over time. All experiments were
performed at room temperature, and the external solution
and drugs were perfused at a rate of 2 mL/min by gravity.
Data were expressed as the ratio of fluorescence due to
excitation at 340 nm and at 380 nm (F340:380). In some
experiments, a nominally Ca2+-free medium was used,
which was identical in composition, except for the omis-
sion of CaCl2.
Statistics
Data are presented as the mean ± SEM, and n indicates the
number of independent experiments or the number of
cells used to measure [Ca2+]i. Statistical significance was
determined using one-way ANOVA or Student's t test; p <
0.05 was considered significant.
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